3.35亿美元首付款!艾伯维盯上小核酸药物开发

时代财经
Yesterday

本文来源:时代财经5月15日,时代财经获悉,艾伯维和ADARx Pharmaceuticals宣布达成合作和许可选择协议,以开发涵盖神经科学、免疫学和肿瘤学等多个疾病领域的小干扰RNA (siRNA) 疗法。此次战略合作将利用ADARx在RNA发现方面的专业知识和专有的siRNA技术,该技术有望实现持续且精准的mRNA沉默。艾伯维将酌情贡献其在抗体工程、抗体药物偶联物(ADC)和组织递送方法方面的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10